Nothing in the lobby of Medtronic’s operational headquarters on Medtronic Parkway in Minneapolis would suggest a company in disarray. It’s a polished, functional building that conveys permanence. However, something has been changing for months within the company’s different business units, which are dispersed from California to Minnesota to Ireland, and the employees there sense it more strongly than any earnings call can.
Medtronic confirmed plans to lay off 81 workers at its Northridge facility, which produces diabetes devices, in February 2026 by filing a Worker Adjustment and Retraining Notification notice in California. The layoffs are scheduled to take effect on April 7.
| Company Information | Values |
|---|---|
| Full Name | Medtronic plc |
| Founded | 1949, Minneapolis, Minnesota |
| Headquarters (Operational) | 710 Medtronic Parkway, Minneapolis, MN, USA |
| Legal Headquarters | Dublin, Ireland |
| CEO | Geoffrey Martha |
| Global Employees | ~95,000+ |
| Stock Ticker | MDT (NYSE) |
| Diabetes Division Employees | 8,000+ globally |
| MiniMed IPO Target Valuation | Up to $7.86 billion |
| 2026 Northridge Layoffs | 81 employees (WARN notice filed Feb. 5, 2026) |
| Reference Website | medtronic.com |
Drug Delivery Company: A structural decision rather than a targeted performance cull is indicated by the cross-functional mix of affected roles, which include engineering, IT, marketing, and technicians. The 81 positions make up about 1% of the Diabetes business’s workforce, which employs over 8,000 people worldwide. In percentage terms, the drug delivery business is small. If your name appears on the list, it’s not small.
The Diabetes division’s impending split into a separate, publicly traded business called MiniMed is cited as the explanation. In its U.S. IPO, MiniMed hopes to raise about $784 million by offering 28 million shares at prices between $25 and $28 each, with a valuation of up to $7.86 billion. Meddatax, which has been a part of Medtronic for almost 25 years—since the initial acquisition for about $3.3 billion back in 2001—that is a momentous occasion on paper.
According to Medtronic, the split will result in “a more focused” business that is more targeted, leaner, and better positioned in high-margin markets. In reality, that wording usually means that people are eliminated before the pitch book is distributed.
Since MiniMed has reported net losses for the past three years, any valuation it receives at IPO must be linked to a reliable route to profitability. Meddatax Investor expectations, boardroom directives, and the kind of restructuring memo that ultimately reaches the staff at the Northridge facility are all examples of how this pressure spreads. It’s possible that the 81 individuals who lost their jobs in April never gave the unit’s debt-to-equity ratio a second thought. They worked as engineers. They worked as technicians. They arrived and constructed things.
It is difficult to ignore the fact that this is not a novel pattern for Medtronic. As part of a larger reorganization involving several business divisions, the company announced in May 2025 that it would be cutting staff at its research facility in Coon Rapids, Minnesota, which would have an impact on R&D positions.
Xtalks CEO Geoffrey Martha of Medtronic laid off 60 workers from its respiratory diagnostics-focused development center in Jerusalem in October 2025, citing plans to streamline operations across fewer global hubs. Xtalks, Every round has been handled as a separate, contained, and necessary modification. When taken as a whole, however, the pattern is more of a gradual, rolling retreat across regions and functions, quarter after quarter, rather than a collection of discrete choices.
The tone on employee forums has shifted from surprise to a more difficult-to-define state of worn-out alertness. Employees have stated that they now anticipate layoffs every quarter, and some have reported internal meetings centered on supplier divestiture, which they interpret as the company being gradually sold off in pieces.
The Layoff:ff Depending on how long you’ve been observing the industry, that may or may not seem like cynicism. Johnson & Johnson, Abbott, and other medtech companies have all undergone major workforce changes in the last two years, so Medtronic is not alone in this. However, this does not lessen the disorienting experience of waiting for your name to show up on a spreadsheet.
The 780G insulin pump has contributed to the unit’s recent growth, and MiniMed recently submitted the next-generation MiniMed Flex to the FDA for approval. MiniMed does bring real product momentum into its IPO. Meddatax is a legitimate company that is still actively creating technology that helps people with diabetes manage their condition on a daily basis. The gadget is still the same. The business environment surrounding it has undergone significant change. And with good reason, those who are constructing it are wondering what version of this company they will continue to work for after the split is finalized.
These aren’t abstract software roles, which is why the Medtronic scenario feels a little different from, say, a tech company cutting staff to finance AI infrastructure. They are engineers who are developing insulin pumps.
They are glucose sensor calibration technicians. The product has different stakes. The mechanics of preparing a spinoff for Wall Street are the main cause of the cuts, rather than the caliber of the work itself. Anonymous sources within the organization claim that in the upcoming months, cuts in certain departments and business units may reach 20%.
The Layoff May 2026 will be far more important than the February WARN notice indicated if that proves to be true. It appears that the Northridge facility served as the appetizer. Those who are still waiting are hoping that someone will disprove that.
